Suven Life Sciences Limited
BSE:530239 Stock Report
Suven Life Sciences Balance Sheet Health
Financial Health criteria checks 5/6 Suven Life Sciences has a total shareholder equity of ₹1.9B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹2.1B and ₹192.8M respectively.
Key information Interest coverage ratio n/a Cash ₹1.66b Equity ₹1.93b Total liabilities ₹192.80m Total assets ₹2.12b
Recent financial health updates
Show all updates
New major risk - Financial position Oct 30
Second quarter 2025 earnings released: ₹2.27 loss per share (vs ₹0.58 loss in 2Q 2024) Oct 30
Suven Life Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024 Sep 26
Suven Pharma Announces Board Changes Sep 20
Suven Life Sciences Limited Announces Step Down of Vaidheesh Annaswamy as Executive Chairperson and Director Sep 19
Suven Life Sciences Announces Positive Topline Results from Phase-2A Proof-Of-Concept Signal Detection Open Label Study of Ropanicant (Suvn-911) for the Treatment of Moderate to Severe Major Depressive Disorder Sep 18
Suven Life Sciences Announces FDA Acceptance of Investigational New Drug (IND) and Grant of Study May Proceed Letter to Initiate Phase-1 Clinical Trial of SUVN-I6107 Aug 27
New minor risk - Share price stability Aug 16
First quarter 2025 earnings released: ₹1.29 loss per share (vs ₹1.10 loss in 1Q 2024) Aug 06
Suven Life Sciences Limited to Report Q1, 2025 Results on Aug 05, 2024 Jul 29
Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023) Jul 07
Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024 May 08
Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023) May 07
Third quarter 2024 earnings released: ₹1.92 loss per share (vs ₹2.90 loss in 3Q 2023) Jan 31
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024 Jan 30
Suven Life Sciences Limited to Report Q3, 2024 Results on Jan 30, 2024 Jan 23
New major risk - Share price stability Jan 16
Suven Life Sciences Limited to Report Q4, 2024 Results on May 15, 2024 Nov 23
Second quarter 2024 earnings released: ₹0.58 loss per share (vs ₹1.59 loss in 2Q 2023) Nov 05
New minor risk - Share price stability Oct 30
Suven Life Sciences Limited to Report Q2, 2024 Results on Nov 04, 2023 Oct 28 Suven Pharma Appoints Sudhir Kumar Singh as CEO
Suven Life Sciences Limited to Report Q1, 2024 Results on Aug 08, 2023 Aug 03
Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.05 loss in FY 2022) Jul 13
Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada Jun 02
Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023 May 10
Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.57 loss in FY 2022) May 10
Third quarter 2023 earnings released: ₹2.90 loss per share (vs ₹2.65 loss in 3Q 2022) Feb 05
Suven Life Sciences Limited to Report Q3, 2023 Results on Feb 02, 2023 Jan 26
Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type Nov 17
Price target decreased to ₹306 Nov 16
Insufficient new directors Nov 16
Second quarter 2023 earnings released Nov 13
Suven Life Sciences Limited to Report Q2, 2023 Results on Nov 08, 2022 Nov 03 Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022
Suven Life Sciences Limited to Report Q1, 2023 Results on Jul 26, 2022 Jul 19
Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021) Jul 14 Suven Life Sciences Limited Declares One-Time Special Dividend for the Financial Year 2021-22, Payable on and from 25 May, 2022
Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021) May 09
Suven Life Sciences Limited, Annual General Meeting, Aug 04, 2022 May 08
Suven Life Sciences Limited to Report Q4, 2022 Results on May 07, 2022 May 03
Price target decreased to ₹306 Apr 27
Insufficient new directors Apr 27
Suven Life Sciences Limited Declares Interim Dividend, Payable on and from 22 February 2022 Feb 09
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Feb 01
Insufficient new directors Jan 01
Insufficient new directors Dec 02
Second quarter 2022 earnings released: ₹2.22 loss per share (vs ₹1.23 loss in 2Q 2021) Oct 27
Price target decreased to ₹306 Jul 26
Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020) Jul 15
Price target increased to ₹472 May 08
Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020) May 05
Suven Life Sciences Limited announced that it has received INR 369.10425 million in funding from Jasti Family Trust Apr 04
Independent Non-Executive Director has left the company Feb 03
Third quarter 2021 earnings released: ₹1.92 loss per share (vs ₹1.79 loss in 3Q 2020) Jan 29
Suven Life Sciences Limited to Report Q3, 2021 Results on Jan 28, 2021 Jan 21
New 90-day high: ₹57.90 Dec 03
First half earnings released Oct 28
New 90-day high: ₹56.45 Sep 18
Insider recently bought ₹1.0m worth of stock Aug 26
New 90-day high - ₹54.50 Aug 24
Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 17, 2020 Aug 14
First quarter earnings released Aug 12
New 90-day high - ₹48.55 Aug 07
Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 11, 2020 Aug 06
Price target raised to ₹537 Jul 23 Suven Life Sciences Limited(BSE:530239) dropped from S&P Global BMI Index Jun 22
Financial Position Analysis
Short Term Liabilities: 530239's short term assets (₹1.9B) exceed its short term liabilities (₹179.3M).
Long Term Liabilities: 530239's short term assets (₹1.9B) exceed its long term liabilities (₹13.5M).
Debt to Equity History and Analysis
Debt Level: 530239 is debt free.
Reducing Debt: 530239 has no debt compared to 5 years ago when its debt to equity ratio was 13.2%.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 530239 has sufficient cash runway for more than a year based on its current free cash flow .
Forecast Cash Runway: 530239 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 8.5% each year
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}